Co-Authors
This is a "connection" page, showing publications co-authored by Lindsay Alpert and Namrata Setia.
Connection Strength
1.931
-
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
Score: 0.708
-
The histological spectrum of ARB-induced gastritis. Histopathology. 2022 Nov; 81(5):653-660.
Score: 0.223
-
Interobserver agreement and the impact of mentorship on the diagnosis of inflammatory bowel disease-associated dysplasia among subspecialist gastrointestinal pathologists. Virchows Arch. 2021 Jun; 478(6):1061-1069.
Score: 0.199
-
Histologic changes caused by injection of a novel submucosal lifting agent for endoscopic resection in GI lesions. Gastrointest Endosc. 2021 02; 93(2):470-476.
Score: 0.192
-
Lymphocytic colitis: pathologic predictors of response to therapy. Hum Pathol. 2018 08; 78:1-7.
Score: 0.163
-
Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry. Arch Pathol Lab Med. 2018 Apr; 142(4):523-528.
Score: 0.162
-
Measuring the Submucosal Depth of Invasion in Endoscopic Mucosal Resections for Barrett-associated Adenocarcinoma: Practical Issues and Relevance for the Decision for Esophagectomy. Arch Pathol Lab Med. 2022 11 01; 146(11):1338-1344.
Score: 0.056
-
Hypermucinous, Goblet Cell-Deficient and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up. J Crohns Colitis. 2022 Jan 28; 16(1):98-108.
Score: 0.054
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.049
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.047
-
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 06; 8(6):696-713.
Score: 0.041
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.040